eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
4/2007
vol. 45
 
Share:
Share:
more
 
 
abstract:

Review paper
The role of abatacept in the treatment of rheumatoid arthritis

Piotr Wiland
,
Bożena Kowalewska
,
Eliza Roszkowska
,
Jacek Szechiński

Reumatologia 2007; 45, 4: 205–214
Online publish date: 2007/08/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Although the development of disease-modifying antirheumatic drugs (DMARDs) and tumour necrosis factor antagonists has improved the clinical outcome of many patients with rheumatoid arthritis (RA), a substantial proportion of patients have an inadequate response. As T cells promote numerous disease pathways in RA, these cells are a logical target for anti-inflammatory therapy. Abatacept (CTLA-4Ig) is a soluble recombinant fusion protein which competes with CD28 for CD80 and CD86 binding and thereby can be used to selectively modulate T-cell activation. Several clinical trials have now confirmed the efficacy of this compound in the treatment of RA. This article discusses the mechanism of action and reviews the data from large clinical trials on the efficacy and safety of abatacept in RA.
keywords:

rheumatoid arthritis, lymphocyte T, abatacept, CD28 antigen





Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe